EPB41L3

Across TCGA pan-cancer cohorts, EPB41L3 Mutation is linked to patient survival in 10 of 34 cancer types, making it a survival-associated EPB41L3 data layer compared with 24 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in small cell lung cancer (SCLC), where higher EPB41L3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EPB41L3 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

SCLC, UCEC, and OV are the cancer types where EPB41L3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SCLC	DFS	Median	II,III,IV	0.137	0.625	<.001	34	view →
UCEC	DFS	Median	II,III,IV	0.870	0.428	.018	16	view →
OV	DFS	Median	III,IV	0.263	0.535	.016	8	view →
SARC	OS	Median	All	0.174	0.860	<.001	6	view →
READ	OS	Median	II,III,IV	0.187	0.653	.030	6	view →
PRAD	DFS	Median	All	0.677	0.936	.006	6	view →
PAAD	OS	Median	II,III,IV	0.117	0.620	.014	3	view →
GBM	OS	Median	All	0.075	0.416	.011	3	view →
LIHC	OS	Median	III,IV	0.270	0.732	.021	3	view →
LUSC	OS	Median	IV	0.851	0.255	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 10 strongest of 10 lineages.

EPB41L3–SCLC (DFS)

Open the SCLC breakdown →